Radiation therapy for the management of patients with HTLV-1-associated adult T-cell leukemia/lymphoma

Charles B. Simone, John C. Morris, Donn M. Stewart, Nicole E. Urquhart, John E. Janik, Robert J. Kreitman, Elena Lita, Kevin Conlon, Gilian Wharfe, Thomas A. Waldmann, Aradhana Kaushal

Research output: Contribution to journalArticlepeer-review

14 Scopus citations


Human T-cell leukemia virus type 1 - associated adult T-cell leukemia/lymphoma (ATL) typically has survivals measured in months with chemotherapy. One prior published series (1983-1991) assessed local radiotherapy for ATL. Ten consecutive patients with pathologically confirmed ATL treated with radiotherapy were reviewed. Subtypes included acute (n = 7), smoldering (n = 2), and lymphomatous (n = 1). Patients received an average of 2.5 systemic therapy regimens before radiotherapy. Twenty lesions (cutaneous = 10, nodal = 8, extranodal = 2) were treated to a mean of 35.4 Gy/2-3 Gy (range, 12-60 Gy). At 9.0-month mean follow-up (range, 0.1-42.0 months), all lesions symptomatically and radiographically responded, with in-field complete responses in 40.0% (nodal 37.5% vs cutaneous 50.0%; P = .62). No patient experienced in-field progression. Nine patients developed new/progressive out-of-field disease. Median survival was 17.0 months (3-year survival, 30.0%). No Radiation Therapy Oncology Group acute grade ≥ 3 or any late toxicity was noted. This report is the first to use modern radiotherapy techniques and finds effective local control acrossATL subtypes. Radiotherapy should be considered for symptomatic local progression of ATL.

Original languageEnglish (US)
Pages (from-to)1816-1819
Number of pages4
Issue number9
StatePublished - Aug 30 2012

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology


Dive into the research topics of 'Radiation therapy for the management of patients with HTLV-1-associated adult T-cell leukemia/lymphoma'. Together they form a unique fingerprint.

Cite this